<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Multi-task Learning of Histology and Molecular Markers for Classifying Diffuse Glioma</title>
				<funder ref="#_g6ERsuu">
					<orgName type="full">National Institute for Health and Care Research</orgName>
					<orgName type="abbreviated">NIHR</orgName>
				</funder>
				<funder>
					<orgName type="full">Guarantors of Brain</orgName>
				</funder>
				<funder ref="#_GY3ueXn">
					<orgName type="full">NIHR Cambridge Biomedical Research Centre</orgName>
				</funder>
				<funder>
					<orgName type="full">NIHR Brain Injury MedTech Co-operative</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher>Springer Nature Switzerland</publisher>
				<availability status="unknown"><p>Copyright Springer Nature Switzerland</p>
				</availability>
				<date type="published" when="2023">2023</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Xiaofei</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical Neurosciences</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephen</forename><surname>Price</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical Neurosciences</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Chao</forename><surname>Li</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Clinical Neurosciences</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Applied Mathematics and Theoretical Physics</orgName>
								<orgName type="institution">University of Cambridge</orgName>
								<address>
									<settlement>Cambridge</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">School of Science and Engineering</orgName>
								<orgName type="institution">University of Dundee</orgName>
								<address>
									<settlement>Dundee</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution">University of Dundee</orgName>
								<address>
									<settlement>Dundee</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Multi-task Learning of Histology and Molecular Markers for Classifying Diffuse Glioma</title>
					</analytic>
					<monogr>
						<title level="m">Lecture Notes in Computer Science</title>
						<idno type="ISSN">0302-9743</idno>
						<idno type="eISSN">1611-3349</idno>
						<imprint>
							<publisher>Springer Nature Switzerland</publisher>
							<biblScope unit="page" from="551" to="561"/>
							<date type="published" when="2023" />
						</imprint>
					</monogr>
					<idno type="MD5">C8F47E2272D482A91AB000537F166025</idno>
					<idno type="DOI">10.1007/978-3-031-43990-2_52</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2024-05-01T10:03+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Diffuse Glioma</term>
					<term>Digital Pathology</term>
					<term>Multi-task learning</term>
					<term>Muti-label Classification</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Most recently, the pathology diagnosis of cancer is shifting to integrating molecular makers with histology features. It is a urgent need for digital pathology methods to effectively integrate molecular markers with histology, which could lead to more accurate diagnosis in the real world scenarios. This paper presents a first attempt to jointly predict molecular markers and histology features and model their interactions for classifying diffuse glioma bases on whole slide images. Specifically, we propose a hierarchical multi-task multi-instance learning framework to jointly predict histology and molecular markers. Moreover, we propose a co-occurrence probability-based label correction graph network to model the co-occurrence of molecular markers. Lastly, we design an inter-omic interaction strategy with the dynamical confidence constraint loss to model the interactions of histology and molecular markers. Our experiments show that our method outperforms other state-of-the-art methods in classifying diffuse glioma, as well as related histology and molecular markers on a multi-institutional dataset.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">Introduction</head><p>Diffuse glioma is the most common and aggressive primary brain tumors in adults, accounting for more deaths than any other type <ref type="bibr">[7]</ref>. Pathology diagnosis is the gold standard for diffuse glioma but is usually time-consuming and highly depends on the expertise of senior pathologists <ref type="bibr" target="#b10">[13]</ref>. Hence, automatic algorithms based on histology whole slide images (WSIs) <ref type="bibr" target="#b12">[15]</ref>, namely digital pathology, promise to offer rapid diagnosis and aid precise treatment.</p><p>Recently, deep learning has achieved success in diagnosing various tumors <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b18">21]</ref>. Most methods are mainly predicting histology based on WSI, less concerning molecular markers. However, the paradigm of pathological diagnosis of glioma has shifted to molecular pathology, reflected by the 2021 WHO Classification of Tumors of the Central Nervous System <ref type="bibr" target="#b11">[14]</ref>. The role of key molecular markers, i.e., isocitrate dehydrogenas (IDH) mutations, co-deletion of chromosome 1p/19q and homozygous deletion (HOMDEL) of cyclin-dependent kinase inhibitor 2A/B (CDKN), have been highlighted as major diagnostic markers for glioma, while histology features that are traditionally emphasized are now considered as reference, although still relevant in many cases. For instance, in the new pathology scheme, glioblastoma is increasingly diagnosed according to IDH mutations, while previously its diagnosis mostly relies on histology features, including necrosis and microvascular proliferation (NMP). 1  However, the primary approaches to assess molecular markers include gene sequencing and immuno-staining, which are time-consuming and expensive than histology assessment. As histology features are closely associated with molecular alterations, algorithm predicting molecular markers based on histology WSIs is feasible and have clinical significance. Moreover, under the new paradigm of integrating molecular markers with histological features into tumor classification, it is helpful to model the interaction of histology and molecular makers for a more accurate diagnosis. Therefore, there is an urgent need for developing novel digital pathology methods based on WSI to predict molecular markers and histology jointly and modeling their interactions for final tumor classification, which could be valuable for the clinically relevant diagnosis of diffuse glioma.</p><p>This paper proposes a deep learning model (DeepMO-Glioma) for glioma classification based on WSIs, aiming to reflect the molecular pathology paradigm. Previous methods are proposed to integrate histology and genomics for tumour diagnosis <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b7">10,</ref><ref type="bibr" target="#b17">20]</ref>. For instance, Chen et al. <ref type="bibr" target="#b2">[3]</ref> proposed a multimodal fusion strategy to integrate WSIs and genomics for survival prediction. Xing et al. <ref type="bibr" target="#b17">[20]</ref> devised a self-normalizing network to encode genomics. Nevertheless, most existing approaches of tumor classification only treat molecular markers as additional input, incapable to simultaneously predict the status of molecular markers, thus clinically less relevant under the current clinical diagnosis scheme. To jointly predict histology and molecular markers following clinical diagnostic pathway, we propose a novel hierarchical multi-task multi-instance learning (HMT-MIL) framework based on vision transformer <ref type="bibr" target="#b3">[4]</ref>, with two partially weight-sharing parts to jointly predict molecular markers and histology.</p><p>Moreover, multiple molecular markers are needed for classifying cancers, due to complex tumor biology. To reflect real-world clinical scenarios, we formulate predicting multiple molecular markers as a multi-label classification (MLC) task. Previous MLC methods have successfully modeled the correlation among labels <ref type="bibr" target="#b9">[12,</ref><ref type="bibr" target="#b19">22]</ref>. For example, Yazici et al. <ref type="bibr" target="#b19">[22]</ref> proposed an orderless recurrent method, while Li et al. designed a label attention transformer network with graph embedding. In medical domain, Zhang et al. <ref type="bibr" target="#b21">[25]</ref> devised a dual-pool contrastive learning for classifying fundus and X-ray images. Despite success, when applied to predicting multiple molecular markers, most existing methods may ignore the co-occurrence of molecular markers, which have intrinsic associations <ref type="bibr" target="#b20">[23]</ref>. Hence, we propose a co-occurrence probability-based, label-correlation graph (CPLC-Graph) network to model the co-occurrence of molecular markers, i.e., intra-omic relationship.</p><p>Lastly, we focus on modeling the interaction between molecular markers and histology. Specifically, we devise a novel inter-omic interaction strategy to model the interaction between the predictions of molecular markers and histology, e.g., IDH mutation and NMP, both of which are relevant in diagnosing glioblastoma. Particularly, we design a dynamical confidence constraint (DCC) loss that constrains the model to focus on similar areas of WSIs for both tasks. To the best of our knowledge, this is the first attempt to classify diffuse gliomas via modeling the interaction of histology and molecular markers.</p><p>Our main contributions are: <ref type="bibr" target="#b0">(1)</ref> We propose a multi-task multi-instance learning framework to jointly predict molecular markers and histology and finally classify diffuse glioma, reflecting the new paradigm of pathology diagnosis. <ref type="bibr" target="#b1">(2)</ref> We design a CPLC-Graph network to model the intra-omic relationship of multiple molecular markers. (3) We design a DCC learning strategy to model the inter-omic interaction between histology and molecular markers for glioma classification.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">Preliminaries</head><p>Database: We use publicly available TCGA GBM-LGG dataset <ref type="bibr">[6]</ref>. Following <ref type="bibr" target="#b12">[15]</ref>, we remove the WSIs of low quality or lack of labels. Totally, we include Training Labels: Original lables for genomic markers and histology of WSIs are obtained from TCGA database <ref type="bibr">[6]</ref>. According to the up-to-date WHO criteria <ref type="bibr" target="#b11">[14]</ref>, we generate the classification labels for each case as grade 4 glioblastoma (defined as IDH widetype), oligodendroglioma (defined as IDH mutant and 1p/19q co-deletion), grade 4 astrocytoma (defined as IDH mutant, 1p/19q non co-deletion with CDKN HOMDEL or NMP), or low-grade astrocytoma (other cases).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">Methodology</head><p>Figure <ref type="figure" target="#fig_0">1</ref> illustrates the proposed DeepMO-Glioma. As shown above, the upto-date WHO criteria incorporates molecular markers and histology features. Therefore, our model is designed to jointly learn the tasks of predicting molecular markers and histology features in a unified framework. DeepMO-Glioma consists four modules, i.e., stem, genomic marker prediction, histology prediction and cross-omics interaction. Given the cropped patches {X i } N 1 as the input, DeepMO-Glioma outputs 1) the status of molecular markers, including IDH mutation lidh ∈ R 2 , 1p/19q co-deletion l1p/19q ∈ R 2 and CDKN HOMDEL lcdkn ∈ R 2 , 2) existence of NMP lnmp ∈ R 2 and 3) final diagnosis of diffuse gliomas lglio ∈ R 4 . Of note, the final diagnosis of diffuse gliomas is generated via a decision tree-based logical function with the input of predicted molecular markers and histology, consistent with the up-to-date WHO criteria.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">Hierarchical Multi-task Multi-instance Learning</head><p>To extract global information from input {X i } N  1 , we propose a hierarchical multi-task multi-instance learning (HMT-MIL) framework for both histology and molecular marker predictions. Different from methods using one <ref type="bibr">[24]</ref> or several <ref type="bibr" target="#b2">[3,</ref><ref type="bibr" target="#b17">20]</ref> representative patches per slide, HMT-MIL framework can extract information from N = 2,500 patches per WSI via utilizing the MIL learning paradigm with transformer blocks <ref type="bibr" target="#b3">[4]</ref> embedded. Note for WSIs with patch number&lt; N, we adopt a biological repeat strategy for dimension alignment. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">Co-occurrence Probability-Based, Label-Correlation Graph</head><p>In predicting molecular markers, i.e., IDH, 1p/19q and CDKN, existing MLC methods based on label correlation may ignore the co-occurrence of the labels. In the genomic marker prediction module, we proposed a co-occurrence probabilitybased, label-correlation graph (CPLC-Graph) network and a label correlation (LC) loss for intra-omic modeling of the co-occurrence probability of the three markers.</p><p>1) CPLC-Graph network: CPLC-Graph (Fig. <ref type="figure" target="#fig_1">2</ref>) is defined as G = (V, E), where V indicates the nodes, while E represents the edges. Given the intermediate features in predicting the three molecular markers subnets</p><formula xml:id="formula_0">F in = [F in i ] 3 i=1 ∈ R 3×C</formula><p>as input nodes, we construct a co-occurrence probability based correlation matrix A ∈ R 3×3 to reflect the relationships among each node feature, with a weight matrix W g ∈ R C×C to update the value of F in . Formally, the output nodes F mid ∈ R 3×C are formulated by a single graph convolutional network layer as</p><formula xml:id="formula_1">F mid = δ(AF in W g ), where A = [A j i ] 3 i,j=1 , A j i = 1 2 p(F in i |F in j )+p(F in j |F in i ) . (1)</formula><p>In (1), δ(•) is an activation function and p(F in i |F in j ) denote the probability of the status of i-th marker given the status of j-th marker. Besides, residual structure is utilized to generate the final output F out of CPLC-Graph network, defined as</p><formula xml:id="formula_2">F out = αF mid + (1 -α)F in ,</formula><p>where α is a graph balancing hyper-parameter.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>2) LC loss:</head><p>In order to fully exploit the co-occurrence probability of different molecular markers, we further devise the LC loss that constrains the similarity between any two output molecular markers F out i and F out j to approach their correspondent co-occurrence probability A j i . Formally, the LC loss is defined as</p><formula xml:id="formula_3">L LC = MSE(A, D cos ), where D cos = [D i,j cos ] 3 i,j=1 , D i,j cos = (F out i ) F out j F out i F out j .<label>(2)</label></formula><p>In <ref type="bibr" target="#b1">(2)</ref>, MSE denotes the function of mean square error, while D i,j cos is the cosine similarity of features F out i and F out j .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">Dynamical Confidence Constraint</head><p>In the cross-omics interaction module, we design a dynamical confidence constraint (DCC) strategy to model the interaction between molecular markers and histological features. Taking IDH and NMP as an example, the final outputs for IDH widetype<ref type="foot" target="#foot_0">2</ref> and NMP predictions can be defined as lwt = N n=1 ω n wt f n wt and lnmp = N n=1 ω n nmp f n nmp , respectively. Note that f n wt and ω n wt are values of the extracted feature and the corresponding decision weight of n-th patch, respectively. We then reorder [ω n wt ] N n=1 to [ω n wt ] N n=1 based on their values. Similarly, we obtain [ω n nmp ] N n=1 for NMP confidence weights. Based on ordered confidence weights, we constrain the prediction networks of histology and molecular markers to focus on the WSI areas important for both predictions, thus modeling inter-omic interactions. Specifically, we achieve the confidence constraint through a novel DCC loss focusing on top K important patches for both prediction. Formally, the DCC loss in m-th training epoch is defined as:</p><formula xml:id="formula_4">L DCC = 1 2K m Km k=1 S(ω k wt , ωnmp ) + S(ω k nmp , ωwt ) , (<label>3</label></formula><formula xml:id="formula_5">)</formula><p>where S(ω k wt , ωnmp ) is the indicator function taking the value 1 when the k-th important patch of IDH widetype is in the set of top K m important patches for NMP, and vice versa. In addition, to facilitate the learning process with DCC loss, we adopt a curriculum-learning based training strategy dynamically focusing on hard-to-learn patches, regarded as the patches with higher decision importance weight, as patches with lower confidence weight, e.g., patches with fewer nuclei, are usually easier to learn in both tasks. Hence, K m is further defined as</p><formula xml:id="formula_6">K m = K 0 β m m 0 . (<label>4</label></formula><formula xml:id="formula_7">)</formula><p>In ( <ref type="formula" target="#formula_6">4</ref>), K 0 and m 0 are hyper-parameters to adjust L DCC in training process.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">Experiments and Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1">Implementation Details</head><p>The proposed DeepMO-Glioma is trained on the training set for 70 epochs, with batch size of 8 and initial learning rate of 0.003 with Adam optimizer <ref type="bibr" target="#b8">[11]</ref> together with weight decay. Key hyper-parameters are listed in Table <ref type="table" target="#tab_0">1</ref> of supplementary material. All hyper-parameters are tuned to achieve the best performance over the validation set. All experiments are conducted on a computer with an Intel(R) Xeon(R) E5-2698 CPU @2.20 GHz, 256 GB RAM and 4 Nvidia Tesla V100 GPUs. Additionally, our method is implemented on PyTorch with Python environment. * We modified baselines to the MIL setting, since they are not originally designed for MIL. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2">Performance Evaluation</head><p>1) Glioma classification. We compare our model with five other state-of-theart methods: CLAM <ref type="bibr" target="#b12">[15]</ref>, TransMIL <ref type="bibr" target="#b13">[16]</ref>, ResNet-18 <ref type="bibr" target="#b4">[5]</ref>, DenseNet-121 <ref type="bibr" target="#b5">[8]</ref> and VGG-16 <ref type="bibr" target="#b14">[17]</ref>. Note CLAM <ref type="bibr" target="#b12">[15]</ref> and TransMIL <ref type="bibr" target="#b13">[16]</ref> are MIL framework, while others are commonly-used image classification methods, set as our baselines.</p><p>The left panel of Table <ref type="table" target="#tab_0">1</ref> shows that DeepMO-Glioma performs the best, achieving at least 6.1%, 13.1%, 3.1% and 11.0% improvement over other models in accuracy, sensitivity, specificity and AUC, respectively, indicating that our model could effectively integrate molecular markers and histology in classifying diffuse gliomas.</p><p>2) Predictions of genomic markers and histology features. From the left panel of Table <ref type="table" target="#tab_1">2</ref>, we observe that DeepMO-Glioma achieves the AUC of 92.0%, 88.1%, 77.2% and 94.5% for IDH mutation, 1p/19q co-deletion, CDKN HOMDEL and NMP prediction, respectively, considerably better than all the comparison models. Figure <ref type="figure" target="#fig_3">3</ref> plots the ROCs of all models, demonstrating the superior performance of our model over other comparison models.</p><p>3) Network interpretability. An additional visualization experiment is conducted based on patch decision scores to test the interpretability of our method. Due to the page limit, the results are presented in supplementary Fig. <ref type="figure" target="#fig_0">1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3">Results of Ablation Experiments</head><p>1) CPLC-Graph network. The right panels of Table <ref type="table" target="#tab_0">1</ref> shows that, by setting graph balancing weight α to 0 for the proposed CPLC-Graph, the accuracy, sensitivity, specificity and F 1 -score decreases by 7.8%, 29.0%, 3.6% and 21.6%, respectively. Similar results are observed for the prediction tasks of molecular markers and histology (Table <ref type="table" target="#tab_1">2</ref>). Also, the ROC of removing the CPLC-Graph network is shown in Fig. <ref type="figure" target="#fig_3">3</ref>. These results indicate the utility of the proposed CPLC-Graph network.</p><p>2) LC loss. The right panels of Table <ref type="table" target="#tab_0">1</ref> shows that the performance after removing LC loss decreases in all metrics, causing a reduction of 6.1%, 15.0%, 4.3% and 9.8%, in accuracy, sensitivity, specificity and F 1 -score, respectively. Similar results for the tasks of molecular marker and histology prediction are observed in the right panel of Table <ref type="table" target="#tab_1">2</ref> with ROCs in Fig. <ref type="figure" target="#fig_3">3</ref>, indicating the effectiveness of the proposed LC loss.</p><p>3) DCC loss. From Table <ref type="table" target="#tab_0">1</ref>, we observe that the proposed DCC loss improves the performance in terms of accuracy by 9.1%. Similar results can be found for sensitivity, specificity and F 1 -score. From Table <ref type="table" target="#tab_1">2</ref>, we observe that the AUC decreases 2.9%, 2.9%, 0.5% and 2.8% for the prediction of IDH, 1p/19q, CDKN and NMP, respectively, when removing the DCC loss. Such performance is also found in comparing the ROCs in Fig. <ref type="figure" target="#fig_3">3</ref>, suggesting the importance of the DCC loss for all the tasks.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">Summary</head><p>The paradigm of pathology diagnosis has shifted to integrating molecular makers with histology features. In this paper, we aim to classify diffuse gliomas under up-to-date diagnosis criteria, via jointly learning the tasks of molecular marker prediction and histology classification. Inputting histology WSIs, our model incorporates a novel HMT-MIL framework to extract global information for both predicting both molecular markers and histology. We also design a CPLC-Graph network and a DCC loss to model both intra-omic and inter-omic interactions. Our experiments demonstrate that our model has achieved superior performance over other state-of-the-art methods, serving as a potentially useful tool for digital pathology based on WSIs in the era of molecular pathology.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc>Fig. 1. Architecture of DeepMO-Glioma.</figDesc><graphic coords="3,58,98,54,47,334,60,259,24" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>2 ,</head><label>2</label><figDesc>633 WSIs from 940 cases, randomly split into training (2,087 WSIs of 752 cases), validation (282 WSIs of 94 cases) and test (264 WSIs of 94 cases) sets. All the WSIs are crop into patches of size 224 px × 224 px at 0.5 µm px -1 .</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 2 .</head><label>2</label><figDesc>Fig. 2. Pipelines of CPLC-Graph network and LC loss.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Fig. 3 .</head><label>3</label><figDesc>Fig. 3. ROCs of our model, comparison and ablation models for predicting 4 molecular markers. Refer to supplementary Fig. 2 for the zoom-in windows of ROCs.</figDesc><graphic coords="7,108,99,191,18,234,25,236,05" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc>Performance of classifying glioma based on WHO 2021 criteria [1]. Method Diffuse glioma classification, % Ablation (w/o), % Ours CLAM TransMIL ResNet* DenseNet* VGG-16* Graph LC loss DCC</figDesc><table><row><cell>Acc.</cell><cell>77.3 71.2</cell><cell>68.2</cell><cell>59.1</cell><cell>62.9</cell><cell>60.6</cell><cell>65.5</cell><cell>71.2</cell><cell>68.2</cell></row><row><cell>Sen.</cell><cell>76.0 62.9</cell><cell>60.2</cell><cell>51.6</cell><cell>52.5</cell><cell>49.8</cell><cell>47.7</cell><cell>61.0</cell><cell>59.8</cell></row><row><cell>Spec.</cell><cell>86.6 82.9</cell><cell>79.9</cell><cell>71.4</cell><cell>83.5</cell><cell>74.5</cell><cell>83.0</cell><cell>82.3</cell><cell>84.7</cell></row><row><cell cols="2">F 1 -score 71.0 60.0</cell><cell>59.2</cell><cell>51.6</cell><cell>50.9</cell><cell>49.6</cell><cell>49.4</cell><cell>61.2</cell><cell>53.5</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc>Performance in predicting genomic markers, histology and ablation studies.</figDesc><table><row><cell></cell><cell></cell><cell cols="8">Ours CLAM TransMIL ResNet DenseNet VGG-16 No Graph No LC loss No DCC</cell></row><row><cell>IDH</cell><cell cols="2">Acc. 86.4 81.4</cell><cell>83.7</cell><cell>67.8</cell><cell>72.0</cell><cell>70.5</cell><cell>80.7</cell><cell>84.1</cell><cell>84.1</cell></row><row><cell></cell><cell>Sen</cell><cell>80.5 93.8</cell><cell>82.3</cell><cell>68.1</cell><cell>70.8</cell><cell>70.8</cell><cell>82.3</cell><cell>82.3</cell><cell>88.5</cell></row><row><cell></cell><cell cols="2">Spec 90.7 72.2</cell><cell>84.8</cell><cell>67.5</cell><cell>72.8</cell><cell>70.2</cell><cell>79.5</cell><cell>85.4</cell><cell>80.8</cell></row><row><cell></cell><cell cols="2">AUC. 92.0 91.1</cell><cell>90.7</cell><cell>72.7</cell><cell>80.3</cell><cell>79.6</cell><cell>86.1</cell><cell>90.8</cell><cell>89.1</cell></row><row><cell cols="3">1p19q Acc. 81.4 81.8</cell><cell>80.3</cell><cell>70.1</cell><cell>72.3</cell><cell>79.2</cell><cell>76.1</cell><cell>84.1</cell><cell>75.0</cell></row><row><cell></cell><cell cols="2">Sen. 75.0 48.3</cell><cell>43.3</cell><cell>71.7</cell><cell>66.7</cell><cell>43.3</cell><cell>75.0</cell><cell>61.7</cell><cell>78.3</cell></row><row><cell></cell><cell cols="2">Spec. 83.3 91.7</cell><cell>91.2</cell><cell>69.6</cell><cell>74.0</cell><cell>89.7</cell><cell>76.5</cell><cell>90.7</cell><cell>74.0</cell></row><row><cell></cell><cell cols="2">AUC. 88.1 82.0</cell><cell>82.9</cell><cell>76.8</cell><cell>77.1</cell><cell>75.5</cell><cell>83.0</cell><cell>86.7</cell><cell>85.2</cell></row><row><cell cols="3">CDKN Acc. 68.6 67.8</cell><cell>60.2</cell><cell>58.7</cell><cell>59.1</cell><cell>58.7</cell><cell>60.2</cell><cell>58.3</cell><cell>60.2</cell></row><row><cell></cell><cell cols="2">Sen. 63.2 65.8</cell><cell>55.9</cell><cell>59.9</cell><cell>57.9</cell><cell>57.2</cell><cell>47.4</cell><cell>38.2</cell><cell>46.1</cell></row><row><cell></cell><cell cols="2">Spec. 75.9 70.5</cell><cell>66.1</cell><cell>57.1</cell><cell>60.7</cell><cell>60.7</cell><cell>77.7</cell><cell>85.7</cell><cell>79.5</cell></row><row><cell></cell><cell cols="2">AUC. 77.2 77.0</cell><cell>65.5</cell><cell>62.8</cell><cell>62.9</cell><cell>59.9</cell><cell>72.6</cell><cell>76.7</cell><cell>76.7</cell></row><row><cell cols="3">NMP Acc. 87.5 83.7</cell><cell>85.6</cell><cell>68.6</cell><cell>69.3</cell><cell>76.9</cell><cell>82.2</cell><cell>84.8</cell><cell>83.0</cell></row><row><cell></cell><cell cols="2">Sen. 85.7 81.4</cell><cell>81.4</cell><cell>62.9</cell><cell>76.4</cell><cell>74.3</cell><cell>81.4</cell><cell>89.3</cell><cell>77.9</cell></row><row><cell></cell><cell cols="2">Spec. 89.5 86.3</cell><cell>90.3</cell><cell>75.0</cell><cell>61.3</cell><cell>79.8</cell><cell>83.1</cell><cell>79.8</cell><cell>88.7</cell></row><row><cell></cell><cell cols="2">AUC. 94.5 90.7</cell><cell>92.7</cell><cell>74.0</cell><cell>74.7</cell><cell>86.1</cell><cell>86.7</cell><cell>93.4</cell><cell>91.7</cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2" xml:id="foot_0"><p>Note that, IDH widetype is incorporated in diagnosing glioblasoma in current clinical paradigm; while previously, diagnosis of glioblasoma is puley based on NMP.</p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><p>Acknowledgments. This work was supported by the <rs type="funder">NIHR Brain Injury MedTech Co-operative</rs> and the <rs type="funder">NIHR Cambridge Biomedical Research Centre</rs> (<rs type="grantNumber">NIHR203312</rs>). This publication presents independent research funded by the <rs type="funder">National Institute for Health and Care Research (NIHR)</rs>. The views expressed are those of the author(s) and not necessarily those of the <rs type="institution">NHS</rs>, the <rs type="institution">NIHR</rs> or the <rs type="institution">Department of Health and Social Care</rs>. XW is grateful for the <rs type="institution">China Scholarship Council (CSC) Cambridge</rs> scholarship. SJP is funded by <rs type="funder">National Institute for Health and Care Research (NIHR)</rs> <rs type="grantName">Clinician Scientist Fellowship</rs> (<rs type="grantNumber">NIHR/CS/009/011</rs>). CL is funded by <rs type="funder">Guarantors of Brain</rs> Fellowship.</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_GY3ueXn">
					<idno type="grant-number">NIHR203312</idno>
				</org>
				<org type="funding" xml:id="_g6ERsuu">
					<idno type="grant-number">NIHR/CS/009/011</idno>
					<orgName type="grant-name">Clinician Scientist Fellowship</orgName>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Information</head><p>The online version contains supplementary material available at https://doi.org/10.1007/978-3-031-43990-2_52.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The 2021 who classification of tumors of the central nervous system: an update on pediatric low-grade gliomas and glioneuronal tumors</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Bale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Rosenblum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain Pathol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">13060</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Clinical-grade computational pathology using weakly supervised deep learning on whole slide images</title>
		<author>
			<persName><forename type="first">G</forename><surname>Campanella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Med</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1301" to="1309" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Pathomic fusion: an integrated framework for fusing histopathology and genomic features for cancer diagnosis and prognosis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">IEEE Trans. Med. Imaging</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="757" to="770" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<monogr>
		<author>
			<persName><forename type="first">A</forename><surname>Dosovitskiy</surname></persName>
		</author>
		<idno type="arXiv">arXiv:2010.11929</idno>
		<title level="m">An image is worth 16x16 words: transformers for image recognition at scale</title>
		<imprint>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="report_type">arXiv preprint</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Deep residual learning for image recognition</title>
		<author>
			<persName><forename type="first">K</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Sun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition</title>
		<meeting>the IEEE Conference on Computer Vision and Pattern Recognition</meeting>
		<imprint>
			<date type="published" when="2016">2016</date>
			<biblScope unit="page" from="770" to="778" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Densely connected convolutional networks</title>
		<author>
			<persName><forename type="first">G</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Van Der Maaten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Q</forename><surname>Weinberger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition</title>
		<meeting>the IEEE Conference on Computer Vision and Pattern Recognition</meeting>
		<imprint>
			<date type="published" when="2017">2017</date>
			<biblScope unit="page" from="4700" to="4708" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer</title>
		<author>
			<persName><forename type="first">S</forename><surname>Imboden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gynecol. Oncol</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="394" to="400" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Predicting prognosis and IDH mutation status for patients with lower-grade gliomas using whole slide images</title>
		<author>
			<persName><forename type="first">S</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Zanazzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hassanpour</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Rep</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">16849</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Kingma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ba</surname></persName>
		</author>
		<idno type="arXiv">arXiv:1412.6980</idno>
		<title level="m">Adam: a method for stochastic optimization</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="report_type">arXiv preprint</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Multi-label video classification via coupling attentional multiple instance learning with label relation graph</title>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pattern Recogn. Lett</title>
		<imprint>
			<biblScope unit="volume">156</biblScope>
			<biblScope unit="page" from="53" to="59" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Clinical practice guidelines for the diagnosis and treatment of adult diffuse glioma-related epilepsy</title>
		<author>
			<persName><forename type="first">S</forename><surname>Liang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="4527" to="4535" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">The 2021 who classification of tumors of the central nervous system: a summary</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Louis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuro Oncol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1231" to="1251" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Data-efficient and weakly supervised computational pathology on whole-slide images</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Y</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Barbieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mahmood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Biomed. Eng</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="555" to="570" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">TransMil: transformer based correlated multiple instance learning for whole slide image classification</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Ji</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Adv. Neural. Inf. Process. Syst</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="2136" to="2147" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<monogr>
		<title level="m" type="main">Very deep convolutional networks for large-scale image recognition</title>
		<author>
			<persName><forename type="first">K</forename><surname>Simonyan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zisserman</surname></persName>
		</author>
		<idno type="arXiv">arXiv:1409.1556</idno>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="report_type">arXiv preprint</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">New developments in existing who entities and evolving molecular concepts: The genitourinary pathology society (gups) update on renal neoplasia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Trpkov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mod. Pathol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1392" to="1424" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Molecular pathology of poorly differentiated and anaplastic thyroid cancer: what do pathologists need to know?</title>
		<author>
			<persName><forename type="first">M</forename><surname>Volante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Papotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tallini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocr. Pathol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="63" to="76" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Discrepancy and gradientguided multi-modal knowledge distillation for pathological glioma grading</title>
		<author>
			<persName><forename type="first">X</forename><surname>Xing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yuan</surname></persName>
		</author>
		<idno type="DOI">10.1007/978-3-031-16443-9_61</idno>
		<ptr target="https://doi.org/10.1007/978-3-031-16443-9_61" />
	</analytic>
	<monogr>
		<title level="m">MICCAI 2022</title>
		<editor>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">Q</forename><surname>Dou</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Fletcher</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">S</forename><surname>Speidel</surname></persName>
		</editor>
		<editor>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</editor>
		<meeting><address><addrLine>Cham</addrLine></address></meeting>
		<imprint>
			<publisher>Springer</publisher>
			<date type="published" when="2022">2022</date>
			<biblScope unit="volume">13435</biblScope>
			<biblScope unit="page" from="636" to="646" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Deep learning-based six-type classifier for lung cancer and mimics from histopathological whole slide images: a retrospective study</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Med</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1" to="14" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Orderless recurrent models for multi-label classification</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">O</forename><surname>Yazici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gonzalez-Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ramisa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Twardowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Weijer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition</title>
		<meeting>the IEEE/CVF Conference on Computer Vision and Pattern Recognition</meeting>
		<imprint>
			<date type="published" when="2020">2020</date>
			<biblScope unit="page" from="13440" to="13449" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yip</surname></persName>
		</author>
		<idno type="arXiv">arXiv:2203.04013</idno>
	</analytic>
	<monogr>
		<title level="m">Mutual contrastive low-rank learning to disentangle whole slide image representations for glioma grading</title>
		<imprint>
			<date type="published" when="2012">2012. 2022</date>
			<biblScope unit="volume">226</biblScope>
			<biblScope unit="page" from="7" to="16" />
		</imprint>
	</monogr>
	<note type="report_type">arXiv preprint</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Triplet attention and dual-pool contrastive learning for clinic-driven multi-label medical image classification</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Dou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Heng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med. Image Anal</title>
		<imprint>
			<biblScope unit="page">102772</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
